After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for Bicycle Therapeutics plc (BCYC) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $1.05, or 4.96%, to $22.23. The Bicycle Therapeutics plc has recorded 7,851 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that Bicycle Therapeutics to Participate in Upcoming Investor Conferences.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Stocks Info
BCYC belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $21.18 and fluctuated between $21.32 as its day high and $19.89 as its day low. The current market capitalization of Bicycle Therapeutics plc is $653.19M. A total of 0.9 million shares were traded on the day, compared to an average of 282.90K shares.
In the most recent transaction, Lee Kevin sold 6,000 shares of BCYC for 29.06 per share on Jan 03. After the transaction, the Chief Executive Officer now owns 326,585 company shares. In a previous transaction on Jan 03, Keen Nicholas sold 1,817 shares at 29.06 per share. BCYC shares that Chief Scientific Officer owns now total 39,160.
Among the insiders who sold shares, Kalowski Lee disposed of 1,815 shares on Jan 03 at a per-share price of $29.06. This resulted in the President and CFO holding 30,685 shares of BCYC after the transaction. In another insider transaction, Crockett Nigel sold 1,801 shares at $29.06 per share on Jan 03. Company shares held by the Chief Business Officer now total 30,699.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for BCYC in the last 3 months, the mean price target is $52.21 with high estimates of $72.00 and low estimates of $33.00. In terms of 52-week highs and lows, BCYC has a high of $50.47 and a low of $12.08.
As of this writing, BCYC has an earnings estimate of -$1.06 per share for the current quarter. EPS was calculated based on a consensus of 15 estimates, with a high estimate of -$0.94 per share and a lower estimate of -$1.2. The company reported an EPS of -$0.9 in the last quarter, which was -5.90% lower than expectations of -$0.85.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 15 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BCYC is Underweight with a score of 4.64. A total of 12 analysts rated the stock as Buy while 1 rated it as Overweight while 2 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.
